Generic Name and Formulations:
Metipranolol HCl 0.3%; oph soln; contains benzalkonium chloride.
Valeant Pharmaceuticals, Inc
Indications for OPTIPRANOLOL:
1 drop twice daily.
History of, or active, bronchial asthma. Severe COPD. Sinus bradycardia. Greater than 1st-degree AV block. Cardiogenic shock. Overt cardiac failure.
Not for use as sole agent in angle-closure glaucoma. History of cardiac failure. Discontinue at first sign of cardiac failure. Cerebrovascular insufficiency. Withdraw gradually before elective surgery. Diabetes. Hyperthyroidism. Myasthenia gravis. History of anaphylaxis. Pregnancy (Cat.C). Nursing mothers.
May potentiate systemic β-blockers, reserpine. Avoid concomitant calcium channel blockers in impaired cardiac function. Caution with adrenergic psychotropics.
Local discomfort. Rarely: conjunctivitis, eyelid dermatitis, blepharitis, blurred vision, tearing, browache, abnormal vision, photophobia, edema. Systemic absorption: bronchospasm, bradycardia, cardiac failure, depression, other β-blocker effects.
Renal and Urology News Articles
- FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
- Urine Cytology May Not Improve Hematuria Evaluation for Bladder Cancer
- Bladder Hydrodistention May Ease Nocturia in Interstitial Cystitis
- Overnight Saline Irrigation May Prevent Early NMIBC Recurrence
- 5 Key Steps to Grow Your New Nephrology or Urology Practice
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)